Upon infection, HIV disseminates throughout the human body within 1–2 weeks. However,
its early cellular targets remain poorly characterized. We used a single-cell approach to …

Studies have demonstrated that intensive ART alone is not capable of eradicating HIV-1, as
the virus rebounds within a few weeks upon treatment interruption. Viral rebound may be …

HIV-1 eradication strategies aim to achieve viral remission in the absence of antiretroviral
therapy (ART). The development of an HIV-1 cure remains challenging due to the latent …

Historically, naive cells have been considered inconsequential to HIV persistence. Here, we
compared the contributions of naive and memory cells to the reservoirs of individuals with a …

Although combination antiretroviral therapy (ART) blocks HIV replication, it is not curative
because infected CD4+ T cells that carry intact, infectious proviruses persist. Understanding …

Combination antiretroviral therapy (cART) controls but does not eradicate HIV infection; HIV
persistence is the principal obstacle to curing infections. The proportion of defective …

Abstract Purpose of Review Computational and mathematical modeling have become a
critical part of understanding in-host infectious disease dynamics and predicting effective …

HIV persistence in blood and distinct body compartments despite long-standing and potent
therapy is one of the major barriers to a cure. Given that the HIV reservoir is established …

Objective: The contribution of HLA-DR+ memory CD4+ T cells to the HIV reservoir during
prolonged antiretroviral therapy is unclear as these cells are commonly excluded when …

Combination antiretroviral therapy (cART) suppresses viral replication but does not cure HIV
infection because a reservoir of infectious (intact) HIV proviruses persists in long-lived CD4+ …